Mr. Stephen Dunn serves as Director of Research for Dawson James Securities where he performs institutional research for both public and private companies in the biotechnology, pharmaceutical and medical device sectors.
Previous to Dawson James, he served as Director of Research for Cabot Adams LLC and held management positions in Business Development, Finance and Operations having worked in over 25 countries in North America, Europe and the Far East with Fortune 500 biomedical companies including Beckman Coulter, Cordis (Johnson & Johnson), St. Jude Medical and Telectronics.
Having over 20 years within the global biomedical industry, Mr. Dunn has negotiated numerous intellectual property licenses, product development agreements, venture funding, M&A and joint ventures with companies such as GlaxoSmithKline, Pharmacia, Novartis, Bayer, Schering AG, Wyeth, Eli Lilly, Pfizer, Genzyme, Martek Biosciences, Fisher Life Sciences, Becton Dickinson, Idec Pharmaceuticals, Ortho Diagnostics, DakoCytomation, Los Alamos and Sandia National Laboratories, the Mayo Clinic Foundation and the Dana-Farber Institute along with dozens of smaller public and private companies throughout the world.
Mr. Dunn is a Registered Investment Advisor, a member of the Licensing Executives Society, BioFlorida, the Association for Investment Management & Research, the American Institute of CPA's and serves as the biotechnology mentor for the Economic Development Corporation as well as a board member for several companies. He is an accomplished speaker on both financial and scientific topics and has been published in several national investment publications. |
